Brain Stimulation Improved Sleep in 75% of Insomnia Patients After Just Two Weeks

For people who lie awake night after night, a new insomnia treatment has produced a striking result: after just two weeks of targeted brain stimulation, 75% of patients reported a meaningful improvement in sleep quality, compared with 33% receiving sham treatment. The difference emerged in a randomized trial of 72 adults, offering an intriguing new direction for people seeking insomnia treatment without medication.

The technique does not stimulate the brain region most people associate with sleep. It targets the cerebellum, a structure better known for coordinating movement. Researchers are increasingly discovering that it also participates in networks involved in emotion and regulation of brain activity.

Two Weeks of Stimulation, a Large Difference

The researchers tested continuous theta-burst stimulation (cTBS), a patterned form of transcranial magnetic stimulation (TMS). Magnetic pulses were delivered to the cerebellum over two weeks. Participants received either genuine stimulation or a sham procedure designed to provide a comparison.

Their main outcome was a reduction of at least three points on the Pittsburgh Sleep Quality Index (PSQI), a questionnaire measuring aspects of perceived sleep quality and disturbance. That threshold was reached by 75% of the active-treatment group, compared with 33.3% in the sham group. In other words, about 42 more people per 100 reached the study's improvement threshold with active stimulation.

Average PSQI scores were also 3.34 points better with active treatment than sham immediately after the course. At the one-month follow-up, the between-group difference was 3.70 points. These were sizeable differences on a scale ranging from zero to 21, where higher scores indicate poorer sleep.

Importantly, an improvement of three points is not the same as complete recovery from insomnia. Nor do questionnaire scores tell us exactly how many extra minutes participants slept. The clear finding is that substantially more people reported meaningful improvements in their sleep experience.

Why Target the Cerebellum for Insomnia?

The cerebellum is usually introduced as the brain's movement-control center. But it connects to broader circuits involved in attention, emotion and behavioral regulation. Disruption in those circuits may matter to insomnia, particularly when persistent arousal and worry make sleep difficult.

The researchers also investigated resting-state brain connectivity with functional MRI. An exploratory analysis identified a change involving the right amygdala and right orbitofrontal cortex that differed significantly over time between the study groups after correction for multiple testing. It is an interesting biological clue, not proof that this connection caused patients to sleep better.

There was another potential benefit: compared with sham stimulation, the active group also showed improvements in insomnia severity, anxiety symptoms and depression ratings after treatment and at the one-month follow-up. That is relevant because difficulty sleeping, worry and mood symptoms often reinforce one another.

No serious adverse events were reported in this small trial. Larger studies will still need to establish the safety and practicality of repeated courses.

Could Brain Stimulation Become a New Insomnia Treatment?

The trial raises an obvious question: could cerebellar TMS eventually offer a non-drug option for chronic insomnia, including people who have not benefited enough from conventional care?

It is a plausible research direction, but the study did not establish that its participants had treatment-resistant insomnia, and it did not directly compare cTBS with established therapies. Cognitive behavioral therapy for insomnia (CBT-I) remains the recommended first-line treatment for chronic insomnia. Unlike this experimental procedure, CBT-I has a substantial evidence base and focuses on the learned patterns and behaviors that maintain sleeplessness.

The most encouraging aspect of the new study is its speed. Two weeks of treatment produced a clear separation from sham stimulation, and the difference remained visible one month later. That makes cerebellar stimulation worth testing in larger, longer trials, ideally including objective sleep measurements and a direct comparison with CBT-I.

What Can Help While New Treatments Are Being Studied?

People struggling with insomnia do not need to wait for experimental brain stimulation. CBT-I, including professionally supported digital programs where available, is an evidence-based starting point. Regular waking times, a dark and comfortable bedroom and attention to evening caffeine can support a better sleep routine, although sleep hygiene alone is not a substitute for CBT-I in chronic insomnia.

Some people also explore glycine supplements as a modest, low-barrier option for sleep complaints. A 2026 review found just three small trials of supplemental glycine addressing sleep outcomes; all reported improvement in at least one measure, but that is not evidence that glycine treats chronic insomnia. Anyone considering a supplement should check for individual contraindications or interactions rather than postponing assessment of persistent sleep problems.

For now, the brain-stimulation results remain an early finding from 72 participants, with mostly subjective sleep outcomes and follow-up limited to one month. Yet the magnitude of the difference is unusually encouraging: a short, targeted course of magnetic stimulation measurably improved the sleep experience of many more patients than a sham procedure. That is a promising new avenue for insomnia research.

Scientific References & Further Reading

• Anchor Study: “Cerebellar Continuous Theta Burst Stimulation for Insomnia Disorder: A Randomized Sham-Controlled Trial.” (Liu X-Y et al. CNS Neuroscience & Therapeutics. 2026. doi:10.1002/cns.71231; PMID:42929074.)
• Clinical Guideline: “Behavioral and psychological treatments for chronic insomnia disorder in adults: AASM clinical practice guideline.” (Edinger JD et al. J Clin Sleep Med. 2021;17:255–262.)
• 2026 Practice Guideline: “Combination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline.” (Buysse DJ et al. J Clin Sleep Med. 2026.)
• Supplement Evidence: “Glycine Bioavailability and Sleep-Related Outcomes Following Oral Glycine and Collagen Supplementation—A Scoping Review.” (Fan Z, Nelson JM, Wallace TC. J Diet Suppl. 2026. doi:10.1080/19390211.2026.2726197.)

---

Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not a substitute for diagnosis, treatment, or individualized medical care.